Latest news

Sept. 14, 21

EG 427 appoints Grzegorz Sarek, Ph.D., as Vice President of Research

May 28, 21

EG 427 is the success story of the month presented by The SATT Network bringing together 13 Technology Transfer Acceleration Companies in France.

Discover the story (in French)

March 1, 2021

EG 427 announces €12 million Series A financing to advance its HSV-1 based gene therapy

  • David Lamond and Stephane Boissel join the company’s board of Directors


EG 427, a biotechnology company developing pinpoint gene therapy, today announced the closing of a €12 million Series A round. The round was led by David Lamond in association with San Francisco based large family offices. The financing will be used to move the company’s leading vector construct forward to clinical trials in neurogenic bladder.

EG 427 focuses on creating a step-change in the gene therapy field by exploiting the natural properties of Herpes Simplex Virus 1 (HSV-1) and in particular its ability to establish lifelong latency in peripheral neurons. The company’s HSV-1-based vectors ensure highly specific and durable expression of transgenes to treat patients with severe, chronic, and localized diseases, starting with peripheral nervous system disorders.


December 11, 2020

EG 427 is one of the laureate of the innovation contest iLab 2020 and received non dilutive funding from Bpifrance to support its innovative preclinical program of gene therapy in the treatment of neurogenic bladder.

April 3, 2020

EG 427 received 360 000 € from Bpifrance to advance the pharmaceutical development of its first gene therapy candidate. The funds are part of Bpifrance’s supports to innovation through its Aide au Développement de l’Innovation (ADI) program.

September 9, 2019

EG 427 Signed an Exclusive License Agreement with SATT Paris-Saclay to Develop a New HSV-1 based gene therapy to treat Neurogenic bladder after spinal cord injury.

May, 2019

Inception of the company and €1.5 million raised in a seed funding round.